453 related articles for article (PubMed ID: 31607439)
1. Even Faster Door-to-Alteplase Times and Associated Outcomes in Acute Ischemic Stroke.
Jung S; Rosini JM; Nomura JT; Caplan RJ; Raser-Schramm J
J Stroke Cerebrovasc Dis; 2019 Dec; 28(12):104329. PubMed ID: 31607439
[TBL] [Abstract][Full Text] [Related]
2. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome?
Fang K; Churilov L; Weir L; Dong Q; Davis S; Yan B
J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920
[TBL] [Abstract][Full Text] [Related]
3. Imaging negative stroke: diagnoses and outcomes in intravenous tissue plasminogen activator-treated patients.
Spokoyny I; Raman R; Ernstrom K; Meyer BC; Hemmen TM
J Stroke Cerebrovasc Dis; 2014; 23(5):1046-50. PubMed ID: 24103663
[TBL] [Abstract][Full Text] [Related]
4. A Decade of Improvement in Door-to-Needle Time Among Acute Ischemic Stroke Patients, 2008 to 2017.
Tong X; Wiltz JL; George MG; Odom EC; Coleman King SM; Chang T; Yin X; ; Merritt RK
Circ Cardiovasc Qual Outcomes; 2018 Dec; 11(12):e004981. PubMed ID: 30557047
[TBL] [Abstract][Full Text] [Related]
5. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
[TBL] [Abstract][Full Text] [Related]
6. Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study.
Wang X; Song L; Yang J; Sun L; Moullaali TJ; Sandset EC; Delcourt C; Lindley RI; Robinson TG; Minhas JS; Arima H; Chalmers J; Kim JS; Sharma V; Wang JG; Pontes-Neto O; Lavados PM; Olavarría VV; Lee TH; Levi C; Martins SO; Thang NH; Anderson CS;
Cerebrovasc Dis; 2019; 48(3-6):207-216. PubMed ID: 31812956
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke.
Liu J; Shi Q; Sun Y; He J; Yang B; Zhang C; Guo R
J Stroke Cerebrovasc Dis; 2019 Apr; 28(4):1126-1132. PubMed ID: 30655038
[TBL] [Abstract][Full Text] [Related]
8. Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study.
Momosaki R; Yasunaga H; Kakuda W; Matsui H; Fushimi K; Abo M
Cerebrovasc Dis; 2016; 42(1-2):41-8. PubMed ID: 26986718
[TBL] [Abstract][Full Text] [Related]
9. Delay to Tissue Plasminogen Activator in Hypertensive Stroke Patients: An Analysis of Delay Duration Across Agents.
Carrera JF; Sorace BJ; Worrall BB; Southerland AM; Chiota-McCollum NA
J Stroke Cerebrovasc Dis; 2020 Feb; 29(2):104525. PubMed ID: 31812455
[TBL] [Abstract][Full Text] [Related]
10. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
Robinson TG; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Demchuk AM; Donnan GA; Kim JS; Lavados PM; Lee TH; Lindley RI; Martins SCO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Nguyen TH; Wang JG; Woodward M; Chalmers J; Anderson CS;
Stroke; 2017 Jul; 48(7):1877-1883. PubMed ID: 28619989
[TBL] [Abstract][Full Text] [Related]
11. Intravenous Thrombolysis After Idarucizumab Application in Acute Stroke Patients-A Potentially Increased Sensitivity of Thrombi to Lysis?
Pretnar Oblak J; Sabovic M; Frol S
J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):768-773. PubMed ID: 30527792
[TBL] [Abstract][Full Text] [Related]
12. Temporal Trends in Clinical Characteristics and Door-to-Needle Time in Patients Receiving Intravenous Tissue Plasminogen Activator: A Retrospective Study of 4 Hospitals in Japan.
Tanaka K; Matsumoto S; Yamada T; Nagano S; Takase KI; Hatano T; Yamasaki R; Kira JI
J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104305. PubMed ID: 31405791
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Intravenous Thrombolytic Therapy in Patients With Acute Posterior Circulation Stroke: A Single-Center Study.
Zhu X; Wang N; Lin H; Zhang P; Chen L; Zhang M; Deng B; Wu T
J Stroke Cerebrovasc Dis; 2020 Feb; 29(2):104537. PubMed ID: 31806454
[TBL] [Abstract][Full Text] [Related]
14. Endovascular Treatment With or Without Prior Intravenous Alteplase for Acute Ischemic Stroke.
Chalos V; LeCouffe NE; Uyttenboogaart M; Lingsma HF; Mulder MJHL; Venema E; Treurniet KM; Eshghi O; van der Worp HB; van der Lugt A; Roos YBWEM; Majoie CBLM; Dippel DWJ; Roozenbeek B; Coutinho JM;
J Am Heart Assoc; 2019 Jun; 8(11):e011592. PubMed ID: 31140355
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Stroke Outcomes of Hub and Spoke Hospital Treated Patients in Mayo Clinic Telestroke Program.
Demaerschalk BM; Boyd EL; Barrett KM; Gamble DM; Sonchik S; Comer MM; Wieser J; Hentz JG; Fitz-Patrick D; Chang YH
J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):2940-2942. PubMed ID: 30146388
[TBL] [Abstract][Full Text] [Related]
16. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
[TBL] [Abstract][Full Text] [Related]
17. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
[TBL] [Abstract][Full Text] [Related]
18. Improvement in Door-to-Needle Time in Patients with Acute Ischemic Stroke via a Simple Stroke Activation Protocol.
Tan BYQ; Ngiam NJH; Sunny S; Kong WY; Tam H; Sim TB; Leong BSH; Bhartendu C; Paliwal PR; Seet RCS; Chan BPL; Teoh HL; Sharma VK; Yeo LLL
J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1539-1545. PubMed ID: 29422380
[TBL] [Abstract][Full Text] [Related]
19. Utilization of Intravenous Tissue Plasminogen Activator and Reasons for Nonuse in Acute Ischemic Stroke in Saudi Arabia.
Al Khathaami AM; Al Bdah B; Tarawneh M; Alskaini M; Alotaibi F; Alshalan A; Almuhraj M; Aldaham D; Alotaibi N
J Stroke Cerebrovasc Dis; 2020 May; 29(5):104761. PubMed ID: 32173225
[TBL] [Abstract][Full Text] [Related]
20. Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100 kg on 3-Month Outcomes in Acute Ischemic Stroke.
Garavaglia J; Sherman J; Yetzer H; Regier M; Smith M
J Stroke Cerebrovasc Dis; 2017 May; 26(5):1041-1046. PubMed ID: 28129994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
